GITNUXREPORT 2026

Mononucleosis Statistics

Mononucleosis is a common viral infection that often causes fatigue, sore throat, and fever.

Alexander Schmidt

Research Analyst specializing in technology and digital transformation trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Fatigue is the most common symptom, affecting 70-100% of mononucleosis patients and lasting 2-3 months on average

Statistic 2

Sore throat occurs in 80-95% of cases, often with exudative pharyngitis resembling strep

Statistic 3

Fever above 38.5°C affects 80-90% of patients for 1-2 weeks duration

Statistic 4

Cervical lymphadenopathy is present in 90-95%, with nodes >2cm in 50%

Statistic 5

Splenomegaly develops in 50-60% of cases, peaking at week 3 post-onset

Statistic 6

Hepatomegaly seen in 10-15%, with mild transaminase elevation in 80-90%

Statistic 7

Rash occurs in 3-15% spontaneously, but 90% if ampicillin given

Statistic 8

Myalgias and arthralgias affect 20-30%, often migratory

Statistic 9

Periorbital edema in 10-15%, giving allergic appearance

Statistic 10

Palatal petechiae present in 25-50% on exam

Statistic 11

Severe fatigue persists >6 months in 10-12% (chronic fatigue syndrome link)

Statistic 12

Headache in 40-60%, often frontal and severe

Statistic 13

Weight loss averages 5-10% body weight in 30% of patients

Statistic 14

Axillary lymphadenopathy in 50%, inguinal in 25%

Statistic 15

Uvular edema occurs in 5-10%, risking airway compromise

Statistic 16

Night sweats in 20-30%, drenching type

Statistic 17

Conjunctivitis mild in 15%, non-purulent

Statistic 18

Cough uncommon (<10%), dry and non-productive

Statistic 19

Abdominal pain from splenomegaly in 15-20%

Statistic 20

Anorexia affects 50%, leading to dehydration in 10%

Statistic 21

Mono spot test (heterophile Ab) positive in 85-90% of cases by week 2

Statistic 22

EBV VCA IgM peaks at 1:640 titer in acute infection, diagnostic >1:160

Statistic 23

PCR detects EBV DNA in blood at >10,000 copies/ml in 95% acute mono

Statistic 24

Lymphocytosis >50% with >10% atypical lymphocytes diagnostic in 90%

Statistic 25

Anti-EA IgG positive in 80% during acute phase, negative post-recovery

Statistic 26

EBNA IgG appears 2-4 months post-infection, lifelong positive

Statistic 27

Throat culture negative for strep in 90% of mono pharyngitis

Statistic 28

Liver enzymes ALT/AST elevated 3-5x normal in 90%

Statistic 29

Heterophile Ab false negative in 10% adults, 25% children

Statistic 30

Flow cytometry shows CD8+ T-cell expansion >30% in acute mono

Statistic 31

Salivary EBV PCR sensitivity 92%, specificity 88% for acute infection

Statistic 32

IgG avidity low (<50%) in acute EBV vs high in past infection

Statistic 33

Bone marrow biopsy rarely shows hemophagocytosis in 5% severe cases

Statistic 34

CMV IgM cross-reactivity in 5% EBV cases, resolved by PCR

Statistic 35

Chest X-ray normal in 95%, infiltrates rare in immunocompromised

Statistic 36

Splenic ultrasound detects enlargement >13cm in 60%

Statistic 37

EBV FISH on lymph node biopsy confirms in 100% atypical cases

Statistic 38

Serum LDH elevated 2x in 70% with complications

Statistic 39

Paul-Bunnell test specificity 95% for heterophile Ab

Statistic 40

Quantitative IgM VCA >40 U/ml diagnostic with 98% PPV

Statistic 41

CSF EBV PCR positive in 20% mono-related meningitis

Statistic 42

Rapid antigen test for strep false positive 2% in mono

Statistic 43

Anti-VCA IgG/IgM ratio <1 acute, >10 past infection

Statistic 44

Peripheral smear atypical lymphs >5% highly suggestive

Statistic 45

In the United States, the annual incidence of infectious mononucleosis is estimated at 45 cases per 100,000 population

Statistic 46

Globally, about 90-95% of adults over 40 years have evidence of past EBV infection causing mononucleosis-like illness

Statistic 47

Among adolescents aged 15-19 years, the incidence rate of symptomatic mononucleosis is 4-8% per year in developed countries

Statistic 48

In the UK, mononucleosis affects approximately 500,000 individuals annually, with peak incidence in spring and autumn

Statistic 49

Seroprevalence of EBV in children under 5 years is 50% in developing countries versus 20% in developed nations

Statistic 50

College students in dormitories have a 15-20% risk of developing mono within the first year

Statistic 51

Males have a slightly higher incidence of symptomatic mononucleosis than females, at 1.2:1 ratio

Statistic 52

In the US, African Americans have lower EBV seropositivity rates (67%) compared to whites (89%) by age 20

Statistic 53

Peak age for primary EBV infection leading to mono is 14-16 years, with 70% of cases in this group

Statistic 54

During pandemics like COVID-19, mono diagnoses dropped by 30% due to social distancing

Statistic 55

EBV primary infection occurs in 90% of cases before age 25 worldwide

Statistic 56

In Australia, indigenous populations show 95% EBV seropositivity by age 5

Statistic 57

Hospitalization rates for mono complications are 1-2% of cases in children under 10

Statistic 58

Seasonal variation shows 60% of mono cases diagnosed between January and May in temperate climates

Statistic 59

EBV reactivation rates in immunocompromised patients reach 20-30% annually

Statistic 60

In Europe, mono incidence is 2-3 per 1,000 in 15-24 year olds

Statistic 61

US military recruits have 10% mono incidence in first 6 months of service

Statistic 62

Global burden: EBV-associated mono contributes to 1.5 million DALYs yearly

Statistic 63

In Japan, adult mono cases are rarer at 1% of EBV infections versus 50% in teens

Statistic 64

Hispanic populations in US show 80% EBV seropositivity by age 12

Statistic 65

Mono outbreaks in schools affect 5-10% of student body over 3 months

Statistic 66

Lifetime risk of symptomatic mono is 25-50% for those infected as teens

Statistic 67

In Canada, incidence peaks at 58/100,000 in 15-19 year olds

Statistic 68

EBV mono is 3x more common in upper socioeconomic groups

Statistic 69

Post-transplant mono incidence is 5-10% in first year

Statistic 70

In India, 70% of mono cases are asymptomatic in children under 10

Statistic 71

Scandinavian countries report lower mono rates (30/100,000) vs US (45/100,000)

Statistic 72

Pregnancy-associated mono risks fetal transmission at 1-2%

Statistic 73

Urban vs rural: urban areas show 2x higher mono incidence due to crowding

Statistic 74

Epstein-Barr Virus (EBV) causes 90% of infectious mononucleosis cases

Statistic 75

EBV is transmitted primarily through saliva, with 30-50% infectivity in kisses lasting over 10 seconds

Statistic 76

Incubation period for EBV mono averages 4-6 weeks, ranging 2-8 weeks post-exposure

Statistic 77

CMV causes 5-10% of heterophile-negative mononucleosis cases mimicking EBV

Statistic 78

Asymptomatic shedding of EBV in saliva persists for 6-12 months post-infection in 20% of cases

Statistic 79

Transmission risk from blood transfusion is 2.5% with EBV-positive donors

Statistic 80

EBV genome integrates into B-cells, with latency type III in acute mono phase

Statistic 81

HHV-6 co-infection occurs in 15% of EBV mono cases, altering presentation

Statistic 82

Airborne transmission of EBV is negligible, <1% of cases, vs 95% salivary

Statistic 83

Viral load peaks at 10^8 copies/ml saliva during acute mono phase

Statistic 84

EBV gp350 glycoprotein is key for salivary gland attachment and transmission

Statistic 85

Sexual transmission risk for EBV is 20-30% higher in oral-genital contact

Statistic 86

Organ transplant recipients have 50% higher EBV transmission from donor organs

Statistic 87

EBV strain B95-8 shows 100-fold higher infectivity in vitro

Statistic 88

Maternal-fetal transmission rate during acute mono is 3.3%

Statistic 89

EBV survives 7 days on surfaces but transmission requires mucosal contact

Statistic 90

Dual EBV/CMV infection doubles transmission efficiency in households

Statistic 91

EBV DNA detectable in semen of 30% infected males during viremia

Statistic 92

Latency-associated nuclear antigen (LANA) promotes lifelong B-cell carriage

Statistic 93

HIV co-infection increases EBV shedding 10-fold

Statistic 94

EBV type 2 strains less common (10%) but higher transmission in immunocompromised

Statistic 95

Fecal-oral transmission negligible (<0.5%) for EBV mono

Statistic 96

EBV infects nasopharynx first, with 10^5-10^6 initial viral particles needed

Statistic 97

Shared utensils transmit EBV in 25% of household exposures over 2 weeks

Statistic 98

Supportive care resolves 95% cases without antivirals

Statistic 99

Splenic rupture risk 0.1-0.5%, avoid contact sports for 4-6 weeks

Statistic 100

Acyclovir shortens viral shedding by 7-10 days but not symptoms

Statistic 101

Corticosteroids used in 5% for airway obstruction, reducing edema 50%

Statistic 102

Bed rest and hydration lead to full recovery in 99% within 4 weeks acute phase

Statistic 103

Chronic active EBV rare (0.05%), rituximab induces remission 70%

Statistic 104

Fatigue resolves in 80% by 3 months, 11% persist >12 months

Statistic 105

No vaccine available, but gp350 trials show 78% efficacy

Statistic 106

Hospitalization needed in 5-10% for dehydration or complications

Statistic 107

Post-mono lymphoma risk elevated 2-4x lifelong

Statistic 108

Avoid aspirin in children due to Reye's syndrome risk (0.01%)

Statistic 109

IVIG effective in X-linked lymphoproliferative disease (80% survival)

Statistic 110

Return to school/work after fever-free 1 week, 90% comply

Statistic 111

Ganciclovir reduces CMV-mono viremia 90% in transplants

Statistic 112

Mortality <0.1% in immunocompetent, 5% in immunocompromised

Statistic 113

Psychological support reduces chronic fatigue by 40% at 6 months

Statistic 114

Spleen size normalizes by 4-6 weeks in 95%, monitor ultrasound

Statistic 115

No routine antiviral prophylaxis recommended, cost-benefit negative

Statistic 116

Hemolytic anemia in 3%, resolves with steroids in 85%

Statistic 117

Long-term: 20% report recurrent sore throats post-mono

1/117

Sources

Trusted by 500+ publications

+497

Imagine being so common that nine out of ten adults carry the virus that causes it, yet mononucleosis remains the stealthy, draining illness you desperately hope to avoid, especially as it peaks among adolescents and young adults.

Key Takeaways

In the United States, the annual incidence of infectious mononucleosis is estimated at 45 cases per 100,000 population
Globally, about 90-95% of adults over 40 years have evidence of past EBV infection causing mononucleosis-like illness
Among adolescents aged 15-19 years, the incidence rate of symptomatic mononucleosis is 4-8% per year in developed countries
Epstein-Barr Virus (EBV) causes 90% of infectious mononucleosis cases
EBV is transmitted primarily through saliva, with 30-50% infectivity in kisses lasting over 10 seconds
Incubation period for EBV mono averages 4-6 weeks, ranging 2-8 weeks post-exposure
Fatigue is the most common symptom, affecting 70-100% of mononucleosis patients and lasting 2-3 months on average
Sore throat occurs in 80-95% of cases, often with exudative pharyngitis resembling strep
Fever above 38.5°C affects 80-90% of patients for 1-2 weeks duration
Mono spot test (heterophile Ab) positive in 85-90% of cases by week 2
EBV VCA IgM peaks at 1:640 titer in acute infection, diagnostic >1:160
PCR detects EBV DNA in blood at >10,000 copies/ml in 95% acute mono
Supportive care resolves 95% cases without antivirals
Splenic rupture risk 0.1-0.5%, avoid contact sports for 4-6 weeks
Acyclovir shortens viral shedding by 7-10 days but not symptoms

Mononucleosis is a common viral infection that often causes fatigue, sore throat, and fever.

Clinical Symptoms

Fatigue is the most common symptom, affecting 70-100% of mononucleosis patients and lasting 2-3 months on average
Sore throat occurs in 80-95% of cases, often with exudative pharyngitis resembling strep
Fever above 38.5°C affects 80-90% of patients for 1-2 weeks duration
Cervical lymphadenopathy is present in 90-95%, with nodes >2cm in 50%
Splenomegaly develops in 50-60% of cases, peaking at week 3 post-onset
Hepatomegaly seen in 10-15%, with mild transaminase elevation in 80-90%
Rash occurs in 3-15% spontaneously, but 90% if ampicillin given
Myalgias and arthralgias affect 20-30%, often migratory
Periorbital edema in 10-15%, giving allergic appearance
Palatal petechiae present in 25-50% on exam
Severe fatigue persists >6 months in 10-12% (chronic fatigue syndrome link)
Headache in 40-60%, often frontal and severe
Weight loss averages 5-10% body weight in 30% of patients
Axillary lymphadenopathy in 50%, inguinal in 25%
Uvular edema occurs in 5-10%, risking airway compromise
Night sweats in 20-30%, drenching type
Conjunctivitis mild in 15%, non-purulent
Cough uncommon (<10%), dry and non-productive
Abdominal pain from splenomegaly in 15-20%
Anorexia affects 50%, leading to dehydration in 10%

Clinical Symptoms Interpretation

If you thought mono was just a bad cold with an identity crisis, consider the sobering truth that this social-life saboteur often condemns 70-100% of its victims to a months-long marathon of profound fatigue, while also routinely hosting a full-body mutiny featuring a fiery sore throat, swollen organs, and a special appearance by drenching night sweats, all just to remind you it's a virus that truly overstays its welcome.

Diagnosis

Mono spot test (heterophile Ab) positive in 85-90% of cases by week 2
EBV VCA IgM peaks at 1:640 titer in acute infection, diagnostic >1:160
PCR detects EBV DNA in blood at >10,000 copies/ml in 95% acute mono
Lymphocytosis >50% with >10% atypical lymphocytes diagnostic in 90%
Anti-EA IgG positive in 80% during acute phase, negative post-recovery
EBNA IgG appears 2-4 months post-infection, lifelong positive
Throat culture negative for strep in 90% of mono pharyngitis
Liver enzymes ALT/AST elevated 3-5x normal in 90%
Heterophile Ab false negative in 10% adults, 25% children
Flow cytometry shows CD8+ T-cell expansion >30% in acute mono
Salivary EBV PCR sensitivity 92%, specificity 88% for acute infection
IgG avidity low (<50%) in acute EBV vs high in past infection
Bone marrow biopsy rarely shows hemophagocytosis in 5% severe cases
CMV IgM cross-reactivity in 5% EBV cases, resolved by PCR
Chest X-ray normal in 95%, infiltrates rare in immunocompromised
Splenic ultrasound detects enlargement >13cm in 60%
EBV FISH on lymph node biopsy confirms in 100% atypical cases
Serum LDH elevated 2x in 70% with complications
Paul-Bunnell test specificity 95% for heterophile Ab
Quantitative IgM VCA >40 U/ml diagnostic with 98% PPV
CSF EBV PCR positive in 20% mono-related meningitis
Rapid antigen test for strep false positive 2% in mono
Anti-VCA IgG/IgM ratio <1 acute, >10 past infection
Peripheral smear atypical lymphs >5% highly suggestive

Diagnosis Interpretation

The bewildering array of tests for Mono essentially means you can diagnose it by finding a teen's tragically elevated titer of misery, a blood smear full of confused-looking lymphocytes, and a spleen that's staging an unsanctioned expansion in the abdominal cavity.

Epidemiology

In the United States, the annual incidence of infectious mononucleosis is estimated at 45 cases per 100,000 population
Globally, about 90-95% of adults over 40 years have evidence of past EBV infection causing mononucleosis-like illness
Among adolescents aged 15-19 years, the incidence rate of symptomatic mononucleosis is 4-8% per year in developed countries
In the UK, mononucleosis affects approximately 500,000 individuals annually, with peak incidence in spring and autumn
Seroprevalence of EBV in children under 5 years is 50% in developing countries versus 20% in developed nations
College students in dormitories have a 15-20% risk of developing mono within the first year
Males have a slightly higher incidence of symptomatic mononucleosis than females, at 1.2:1 ratio
In the US, African Americans have lower EBV seropositivity rates (67%) compared to whites (89%) by age 20
Peak age for primary EBV infection leading to mono is 14-16 years, with 70% of cases in this group
During pandemics like COVID-19, mono diagnoses dropped by 30% due to social distancing
EBV primary infection occurs in 90% of cases before age 25 worldwide
In Australia, indigenous populations show 95% EBV seropositivity by age 5
Hospitalization rates for mono complications are 1-2% of cases in children under 10
Seasonal variation shows 60% of mono cases diagnosed between January and May in temperate climates
EBV reactivation rates in immunocompromised patients reach 20-30% annually
In Europe, mono incidence is 2-3 per 1,000 in 15-24 year olds
US military recruits have 10% mono incidence in first 6 months of service
Global burden: EBV-associated mono contributes to 1.5 million DALYs yearly
In Japan, adult mono cases are rarer at 1% of EBV infections versus 50% in teens
Hispanic populations in US show 80% EBV seropositivity by age 12
Mono outbreaks in schools affect 5-10% of student body over 3 months
Lifetime risk of symptomatic mono is 25-50% for those infected as teens
In Canada, incidence peaks at 58/100,000 in 15-19 year olds
EBV mono is 3x more common in upper socioeconomic groups
Post-transplant mono incidence is 5-10% in first year
In India, 70% of mono cases are asymptomatic in children under 10
Scandinavian countries report lower mono rates (30/100,000) vs US (45/100,000)
Pregnancy-associated mono risks fetal transmission at 1-2%
Urban vs rural: urban areas show 2x higher mono incidence due to crowding

Epidemiology Interpretation

Though it may seem like a rite of passage, the sneaky Epstein-Barr virus has already kissed most adults by forty, lies in wait to ambush crowded teens, and proves that misery, while loving company, is a remarkably picky host.

Etiology and Transmission

Epstein-Barr Virus (EBV) causes 90% of infectious mononucleosis cases
EBV is transmitted primarily through saliva, with 30-50% infectivity in kisses lasting over 10 seconds
Incubation period for EBV mono averages 4-6 weeks, ranging 2-8 weeks post-exposure
CMV causes 5-10% of heterophile-negative mononucleosis cases mimicking EBV
Asymptomatic shedding of EBV in saliva persists for 6-12 months post-infection in 20% of cases
Transmission risk from blood transfusion is 2.5% with EBV-positive donors
EBV genome integrates into B-cells, with latency type III in acute mono phase
HHV-6 co-infection occurs in 15% of EBV mono cases, altering presentation
Airborne transmission of EBV is negligible, <1% of cases, vs 95% salivary
Viral load peaks at 10^8 copies/ml saliva during acute mono phase
EBV gp350 glycoprotein is key for salivary gland attachment and transmission
Sexual transmission risk for EBV is 20-30% higher in oral-genital contact
Organ transplant recipients have 50% higher EBV transmission from donor organs
EBV strain B95-8 shows 100-fold higher infectivity in vitro
Maternal-fetal transmission rate during acute mono is 3.3%
EBV survives 7 days on surfaces but transmission requires mucosal contact
Dual EBV/CMV infection doubles transmission efficiency in households
EBV DNA detectable in semen of 30% infected males during viremia
Latency-associated nuclear antigen (LANA) promotes lifelong B-cell carriage
HIV co-infection increases EBV shedding 10-fold
EBV type 2 strains less common (10%) but higher transmission in immunocompromised
Fecal-oral transmission negligible (<0.5%) for EBV mono
EBV infects nasopharynx first, with 10^5-10^6 initial viral particles needed
Shared utensils transmit EBV in 25% of household exposures over 2 weeks

Etiology and Transmission Interpretation

The Epstein-Barr virus is a master of the long game, patiently incubating for weeks before launching a salivary siege so effective that a passionate kiss is a coin flip for infection, yet it balks at a mere handshake, proving that true commitment, even for a virus, requires intimate contact.

Management and Prognosis

Supportive care resolves 95% cases without antivirals
Splenic rupture risk 0.1-0.5%, avoid contact sports for 4-6 weeks
Acyclovir shortens viral shedding by 7-10 days but not symptoms
Corticosteroids used in 5% for airway obstruction, reducing edema 50%
Bed rest and hydration lead to full recovery in 99% within 4 weeks acute phase
Chronic active EBV rare (0.05%), rituximab induces remission 70%
Fatigue resolves in 80% by 3 months, 11% persist >12 months
No vaccine available, but gp350 trials show 78% efficacy
Hospitalization needed in 5-10% for dehydration or complications
Post-mono lymphoma risk elevated 2-4x lifelong
Avoid aspirin in children due to Reye's syndrome risk (0.01%)
IVIG effective in X-linked lymphoproliferative disease (80% survival)
Return to school/work after fever-free 1 week, 90% comply
Ganciclovir reduces CMV-mono viremia 90% in transplants
Mortality <0.1% in immunocompetent, 5% in immunocompromised
Psychological support reduces chronic fatigue by 40% at 6 months
Spleen size normalizes by 4-6 weeks in 95%, monitor ultrasound
No routine antiviral prophylaxis recommended, cost-benefit negative
Hemolytic anemia in 3%, resolves with steroids in 85%
Long-term: 20% report recurrent sore throats post-mono

Management and Prognosis Interpretation

The takeaway is that while mono is mostly a tedious but self-resolving slog, it has a darkly comic portfolio of rare but severe complications, so follow the sensible rules—rest, hydrate, and for heaven's sake, don't let your kid play linebacker or take aspirin.

Sources & References

Logos provided by Logo.dev